CFDE Data Portal | Search ZEB2P1

	Label	Description
	ZEB2P1 associations Collection (Entity type)	Associations for ZEB2P1_associations
	ZEB2P1 associations.tsv File (Entity type)	A file from IDG as part of the Harmonizome project
	ZEB2P1 Gene (Entity type)	ENSG00000249506 - zinc finger E-box binding homeobox 2 pseudogene 1
	GSE195663 cisplatin 0 v 3 human dn Gene Set (Entity type)	A Gene Set from LINCS
	GSE212231 GSE218491 SHP2 inhibition 3 v 4 human up Gene Set (Entity type)	A Gene Set from LINCS
	GSE172494 nicotinamide 3 v 1 human dn Gene Set (Entity type)	A Gene Set from LINCS
	GSE195663 cisplatin 7 v 3 human dn Gene Set (Entity type)	A Gene Set from LINCS
	GSE202434 GSE202438 talazoparib 8 v 0 human up Gene Set (Entity type)	A Gene Set from LINCS
	GTEx Pituitary 20-29 vs 70-79 Down Gene Set (Entity type)	A Gene Set from GTEx
	GTEx Pituitary 20-29 vs 50-59 Down Gene Set (Entity type)	A Gene Set from GTEx

ZEB2P1 associations

Associations for ZEB2P1_associations

ZEB2P1 associations.tsv

A file from IDG as part of the Harmonizome project

ZEB2P1

ENSG00000249506 - zinc finger E-box binding homeobox 2 pseudogene 1

GSE195663 cisplatin 0 v 3 human dn

A Gene Set from LINCS

GSE212231 GSE218491 SHP2 inhibition 3 v 4 human up

A Gene Set from LINCS

GSE172494 nicotinamide 3 v 1 human dn

A Gene Set from LINCS

GSE195663 cisplatin 7 v 3 human dn

A Gene Set from LINCS

GSE202434 GSE202438 talazoparib 8 v 0 human up

A Gene Set from LINCS

GTEx Pituitary 20-29 vs 70-79 Down

A Gene Set from GTEx

GTEx Pituitary 20-29 vs 50-59 Down

A Gene Set from GTEx

DISPLAY PER PAGE

@CFDE Workbench 2026

The CFDE Workbench is actively being developed and maintained by the CFDE Data Resource Center (DRC).The DRC is funded by OT2OD036435 from the Common Fund at the National Institutes of Health.

The CFDE Workbench is actively being developed and maintained by the CFDE Data Resource Center (DRC).The DRC is funded by OT2OD036435 from the Common Fund at the National Institutes of Health.

@CFDE Workbench 2026

This repository is under review for potential modification in compliance with Administration directives.